National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting, 58320-58321 [2013-22981]
Download as PDF
<![CDATA[
58320
Federal Register / Vol. 78, No. 184 / Monday, September 23, 2013 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS, GENERATION 3 COHORT AND OMNI GROUP 2 COHORT
Number of
responses per
respondent
Number of
respondents
Type of respondent
I. PARTICIPANT COMPONENTS—ANNUAL FOLLOW-UP
A. Records Request .................................................................................
B. Health Status Update ...........................................................................
Average time
per response
(in hours)
Total annual
burden hour
3212
3212
1
1
15/60
15/60
803
803
SUB-TOTAL: PARTICIPANT COMPONENTS ..................................
II. NON-PARTICIPANT COMPONENTS—ANNUAL FOLLOW-UP
A. Informant contacts ...............................................................................
B. Records Request .................................................................................
* 3212
........................
........................
1606
160
1060
1
1
10/60
15/60
27
265
SUB-TOTAL: NON-PARTICIPANT COMPONENTS ........................
1220
........................
........................
292
* Number of participants as reflected in Rows I.A. and I.B. above.
SUMMARY OF 3 TABLES COMBINED—TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of respondents
Number of responses per
respondent
Participants ......................................................................................................
Non-Participants ..............................................................................................
5564
3816
1
1
36/60
14.5/60
3344
920
Totals ........................................................................................................
9380
........................
........................
4264
Type of respondent
Average time
per response
(in hours)
Total annual
burden hour
(NOTE: reported and calculated numbers differ slightly due to rounding.)
Lynn Susulske,
NHLBI Project Clearance Liaison, National
Institutes of Health.
Michael Lauer,
Director, DCVS, National Institutes of Health.
[FR Doc. 2013–23060 Filed 9–20–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
emcdonald on DSK67QTVN1PROD with NOTICES
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 USC,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel GOMED:
Grand Opportunity in Medications
Development for Substance-Related
Disorders (U01).
Date: October 15, 2013.
VerDate Mar<15>2010
20:16 Sep 20, 2013
Jkt 229001
Time: 9:00 a.m. to 11:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Washington, DC/
Bethesda, 7301 Waverly Street, Bethesda, MD
21045.
Contact Person: Jose F. Ruiz, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, Room 4228, MSC 9550,
6001 Executive Blvd., Bethesda, MD 20892–
9550, (301) 451–3086, ruizjf@nida.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel Strategic
Alliances for Medications Development to
Treat Substance Use Disorders (R01) (PAS–
12–122).
Date: October 15, 2013.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Washington, DC/
Bethesda, 7301 Waverly Street, Bethesda, MD
21045.
Contact Person: Jose F. Ruiz, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, Room 4228, MSC 9550,
6001 Executive Blvd., Bethesda, MD 20892–
9550, (301) 451–3086, ruizjf@nida.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Medications Development Centers of
Excellence Cooperative Program.
Date: October 15–16, 2013.
Time: 2:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Washington, DC/
Bethesda, 7301 Waverly Street, Bethesda, MD
21045.
Contact Person: Jose F. Ruiz, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Drug Abuse, NIH, Room 4228, MSC 9550,
6001 Executive Blvd., Bethesda, MD 20892–
9550, (301) 451–3086, ruizjf@nida.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 17, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–22992 Filed 9–20–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
E:\FR\FM\23SEN1.SGM
23SEN1
Federal Register / Vol. 78, No. 184 / Monday, September 23, 2013 / Notices
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Arthritis and
Musculoskeletal and Skin Diseases Initial
Review Group; Arthritis and Musculoskeletal
and Skin Diseases Clinical Trials Review
Committee.
Date: October 15–16, 2013.
Time: 8:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Charles H Washabaugh,
Ph.D., Scientific Review Officer, Scientific
Review Branch, NIAMS/NIH, 6701
Democracy Boulevard, Suite 800, Bethesda,
MD 20892, 301–594–4952, washabac@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
Dated: September 17, 2013.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–22981 Filed 9–20–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
emcdonald on DSK67QTVN1PROD with NOTICES
National Heart, Lung, and Blood
Institute; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Heart, Lung, and Blood
Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Advisory Council.
VerDate Mar<15>2010
20:16 Sep 20, 2013
Jkt 229001
Date: October 22, 2013.
Open: 8:00 a.m. to 1:00 p.m.
Agenda: To discuss program policies and
issues.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Bethesda, MD
20892.
Closed: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Bethesda, MD
20892.
Contact Person: Stephen C. Mockrin, Ph.D.,
Director, Division of Extramural Research
Activities, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701
Rockledge Drive, Room 7100, Bethesda, MD
20892, (301) 435–0260, mockrins@
nhlbi.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
www.nhlbi.nih.gov/meetings/nhlbac/
index.htm, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: September 17, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–22985 Filed 9–20–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
58321
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel NCI,
Omnibus Cancer Imaging.
Date: October 23, 2013.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
3W034, Rockville, MD 20850, (Telephone
Conference Call).
Contact Person: Thomas A. Winters, Ph.D.,
Scientific Review Officer, Special Review &
Logistics Branch, Division of Extramural
Activities, 9609 Medical Center Drive, Room
7W412, National Cancer Institute, NIH,
Bethesda, MD 20892–9750, 240–276–6386,
twinters@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Cancer
Management, Epidemiology, and Health
Behavior Meeting.
Date: October 29–30, 2013.
Time: 8:30 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Ellen K Schwartz, EDD,
MBA, Scientific Review Officer, Special
Review and Logistics Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W264, Bethesda, MD 20892–8329,
240–276–6384, schwarel@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, R13
Applications.
Date: October 30, 2013.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W556, Rockville, MD 20850, (Telephone
Conference Call).
Contact Person: Bratin K. Saha, Ph.D.,
Scientific Review Officer, Program
Coordination and Referral Branch, Division
of Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W556, Rockville, MD 20850, 240–
276–6411, sahab@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Provocative
Questions: Cancer Therapy & Outcomes.
Date: November 7–8, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Eun Ah Cho, Ph.D.,
Scientific Review Officer, Special Review
E:\FR\FM\23SEN1.SGM
23SEN1
]]>Agencies
[Federal Register Volume 78, Number 184 (Monday, September 23, 2013)]
[Notices]
[Pages 58320-58321]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-22981]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin
Diseases; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which
[[Page 58321]]
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Arthritis and Musculoskeletal and Skin
Diseases Initial Review Group; Arthritis and Musculoskeletal and
Skin Diseases Clinical Trials Review Committee.
Date: October 15-16, 2013.
Time: 8:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda North Marriott Hotel & Conference Center, 5701
Marinelli Road, Bethesda, MD 20852.
Contact Person: Charles H Washabaugh, Ph.D., Scientific Review
Officer, Scientific Review Branch, NIAMS/NIH, 6701 Democracy
Boulevard, Suite 800, Bethesda, MD 20892, 301-594-4952,
washabac@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.846,
Arthritis, Musculoskeletal and Skin Diseases Research, National
Institutes of Health, HHS)
Dated: September 17, 2013.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-22981 Filed 9-20-13; 8:45 am]
BILLING CODE 4140-01-P
